SCHEMBL27586293

SCHEMBL27586293

CCCN1CCC(NC(=O)c2ccc(OCC3(c4cc(C)nc5ccccc45)CNCCO3)cc2)(C(C)C(=O)NO)CC1

nearest known ligand 0.51

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 18/20 0.51
MMP13 P45452 1/20 0.45
ADAMTS4 O75173 2/20 0.43
MMP3 P08254 2/20 0.43
MMP7 P09237 2/20 0.43
ADAMTS1 Q9UHI8 2/20 0.43
ADAMTS5 Q9UNA0 2/20 0.43
MMP8 P22894 1/20 0.43
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6594265 0.82 ADAM17 (0.73) ADAM17MMP13MMP2MMP9
SCHEMBL27586308 0.80 ADAM17 (0.58) ADAM17MMP13ADAMTS4MMP3MMP7
SCHEMBL27566900 0.76 ADAM17 (0.58) ADAM17MMP13ADAMTS4MMP3MMP7
SCHEMBL27566855 0.75 ADAM17 (0.52) ADAM17MMP13ADAMTS4MMP3MMP7
SCHEMBL6596966 0.74 ADAM17 (0.71) ADAM17MMP13ADAMTS4MMP3MMP7
SCHEMBL6596235 0.73 ADAM17 (0.64) ADAM17MMP13MMP2MMP9
SCHEMBL6597542 0.73 ADAM17 (0.71) ADAM17MMP13ADAMTS4MMP3MMP7
SCHEMBL6595325 0.71 ADAM17 (0.74) ADAM17MMP13MMP2
SCHEMBL6597835 0.70 ADAM17 (0.67) ADAM17MMP13ADAMTS4MMP3MMP7
Trifluoroacetic Acid SCHEMBL6597061 0.69 ADAM17 (0.66) ADAM17MMP13ADAMTS4MMP3MMP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1420881-A Beta-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-alpha BRISTOL MYERS SQUIBB PHARMACEU (US) 2003-05-28 CN claimed
CN-1420881-A Beta-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-alpha BRISTOL MYERS SQUIBB PHARMACEU (US) 2003-05-28 CN disclosed